Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patent Troll Bill Clears House; Provisions Problematic For PhRMA Remain

This article was originally published in The Pink Sheet Daily

Executive Summary

Amendments make things a little better for drug firms as attention now shifts to the Senate version.


Related Content

Government Briefs: White House Moves On Patent Reform, DOJ Settles Endo Off-Label Complaints
Drug Firms Ask Senate For Narrow Patent Troll Bill
PTO’s New Deputy Director To Push For “Good IP Policy” Across Industries
Patent Bill Aims For Trolls, But Will It Snare Rx Firms Instead?
White House Credits Eli Lilly With Help In Final Deal On Patent Reform Bill


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts